Generic Name and Formulations:
Metipranolol HCl 0.3%; oph soln; contains benzalkonium chloride.
Bausch Health Companies Inc.
Indications for OPTIPRANOLOL:
1 drop twice daily.
History of, or active, bronchial asthma. Severe COPD. Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure.
Not for use as sole agent in angle-closure glaucoma. History of cardiac failure. Discontinue at first sign of cardiac failure. Cerebrovascular insufficiency. Withdraw gradually before elective surgery. Diabetes. Hyperthyroidism. Myasthenia gravis. History of anaphylaxis. Pregnancy (Cat.C). Nursing mothers.
May potentiate systemic β-blockers, reserpine. Avoid concomitant calcium channel blockers in impaired cardiac function. Caution with adrenergic psychotropics.
Local discomfort. Rarely: conjunctivitis, eyelid dermatitis, blepharitis, blurred vision, tearing, browache, abnormal vision, photophobia, edema. Systemic absorption: bronchospasm, bradycardia, cardiac failure, depression, other β-blocker effects.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Minority Residents Experience Burdens Linked to Race/Ethnicity
- Tips Provided for Budgeting in Medical Residency
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis